Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004192 · ClinicalTrials.gov registry record · Phase 2
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00004192 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 60 participants.
The verdict
NCT00004192, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Colony-stimulating factors may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to compare the effectiveness of filgrastim-SD/01 with that of filgrastim to relieve the neutropenia following combination chemotherapy in patients who have non-Hodgkin's lymphoma.
Interventions
- DRUG cisplatin
- DRUG etoposide
- BIOLOGICAL filgrastim
- DRUG cytarabine
- BIOLOGICAL pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2000-05-01 |
| Est. Completion | 2001-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004192
The ClinicalTrials.gov registry entry for NCT00004192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00004192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004192 about?
NCT00004192 is a clinical study titled "Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma". RATIONALE: Colony-stimulating factors may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Randomized phase II trial to compare the effectiveness of filgrastim-SD/01 with that o...
What is the current status of trial NCT00004192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2000-05-01. Estimated completion is 2001-03-16.
What interventions are being tested in trial NCT00004192?
The interventions under investigation include: cisplatin (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL), cytarabine (DRUG), pegfilgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004192?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.